Savient amps Krystexxa launch with payer focus

Savient Pharmaceuticals has launched its gout drug Krystexxa, deploying a mix of sales reps, education specialists and business managers to help expedite reimbursement from payers, executives said. Report

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.